Vemulapalli Sreekanth, Dolor Rowena J, Hasselblad Vic, Subherwal Sumeet, Schmit Kristine M, Heidenfelder Brooke L, Patel Manesh R, Schuyler Jones W
Division of Cardiology, Duke University Medical Center, Durham, North Carolina.
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Clin Cardiol. 2015 Jun;38(6):378-86. doi: 10.1002/clc.22406. Epub 2015 May 12.
There are limited data on the comparative effectiveness of medical therapy, supervised exercise, and revascularization to improve walking and quality of life in patients with intermittent claudication (IC).
Supervised exercise and revascularization was superior to medical therapy in IC.
We studied the comparative effectiveness of exercise training, medications, endovascular intervention, and surgical revascularization on outcomes including functional capacity (walking distance and timing), quality of life, and mortality. We searched PubMed, EMBASE, and the Cochrane Database of Systematic Reviews from January 1995 to August 2012 for relevant English-language studies. Two investigators independently collected data. Meta-analyses with random-effects models of direct comparisons were supplemented by mixed-treatment analyses to incorporate data from placebo comparisons, head-to-head comparisons, and multiple treatment arms.
Thirty-five unique studies evaluated treatment modalities in 7475 patients with IC. Compared with usual care, only exercise training improved both maximal walking distance (150 meters; 95% confidence interval: 35-266 meters, P = 0.01) and initial claudication distance (39 meters; 95% confidence interval: 9-65 meters, P = 0.003). All modalities were associated with improved quality of life (Short Form-36 physical functioning score) compared with usual care, but there were no differences between treatments. There were insufficient safety data to assess treatment-related complications. All-cause mortality was not significantly different between modalities.
Evidence is insufficient to determine treatment superiority for improving quality of life and walking parameters in IC patients. Further studies with attention to study design, standardized efficacy and safety endpoints, and appropriate subgroup reporting are necessary to determine comparative effectiveness.
关于药物治疗、监督下运动以及血运重建改善间歇性跛行(IC)患者步行能力和生活质量的比较有效性的数据有限。
在IC患者中,监督下运动和血运重建优于药物治疗。
我们研究了运动训练、药物、血管内介入和外科血运重建对包括功能能力(步行距离和时间)、生活质量和死亡率等结局的比较有效性。我们检索了1995年1月至2012年8月期间的PubMed、EMBASE和Cochrane系统评价数据库,以查找相关的英文研究。两名研究者独立收集数据。采用直接比较的随机效应模型进行荟萃分析,并辅以混合治疗分析,以纳入来自安慰剂对照、直接比较和多个治疗组的数据。
35项独特的研究评估了7475例IC患者的治疗方式。与常规治疗相比,只有运动训练改善了最大步行距离(150米;95%置信区间:35 - 266米,P = 0.01)和初始跛行距离(39米;95%置信区间:9 - 65米,P = 0.003)。与常规治疗相比,所有治疗方式均与生活质量改善(简短健康调查问卷身体功能评分)相关,但各治疗组之间无差异。没有足够的安全性数据来评估与治疗相关的并发症。各治疗方式之间的全因死亡率无显著差异。
证据不足以确定在改善IC患者生活质量和步行参数方面哪种治疗更具优势。需要进一步开展研究,关注研究设计、标准化的疗效和安全性终点以及恰当的亚组报告,以确定比较有效性。